Page 16 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID

Expanded Umbilical Cord Mesenchymal Stem Cells as a Strategy In Managing COVID-19 Illness

63:457-460. 60. Khatri M, Richardson LA, Meulia from the umbilical cord for newly-onset
48. Lu R, Zhao X, Li J, et al. Genomic T. Mesenchymal stem cell-derived type 1 diabetes mellitus. Endocr J 2013;
characterisation and epidemiology of extracellular vesicles attenuate influenza 60:347-357.
2019 novel coronavirus: implications virus-induced acute lung injury in a pig 71. Riordan NH, Morales I, Fernández G, et
for virus origins and receptor binding. model. Stem Cell Res Ther 2018; 9:17. al. Clinical feasibility of umbilical cord
Lancet 2020; 395:565-574. 61. Chen F, Liang P, Ye F, Hou CC, Pi L. tissue-derived mesenchymal stem cells
49. Zhou P, Yang XL, Wang XG, et al. A Mesenchymal stem cell therapy for in the treatment of multiple sclerosis. J
pneumonia outbreak associated with a patients with ischemic heart failure Transl Med 2018; 16:57.
new coronavirus of probable bat origin. -past, present, and future. Curr Stem 72. Dasari VR, Veeravalli KK, Dinh DH.
Nature 2020; 579:270-273. Cell Res Ther 2020 Mar 9. [Epub ahead of Mesenchymal stem cells in the treatment
50. Kuba K, Imai Y, Rao SA, et al. A crucial print] of spinal cord injuries: A review. World J
role of angiotensin converting enzyme 62. Bartolucci J, Verdugo FJ, González PL, et Stem Cells 2014; 6:120-133.
2 (ACE2) in SARS coronavirus-induced al. Safety and efficacy of the intravenous 73. Daley GQ. The promise and perils of
lung injury. Nat Med 2005; 11:875-879. infusion of umbilical cord mesenchymal stem cell therapeutics. Cell Stem Cell
stem cells in patients with heart failure:
51. Ge XY, Li JL, Yang XL, et al. Isolation 2012; 10:740-749.
and characterization of a bat SARS-like A Phase 1/2 randomized controlled trial 74. Navani A, Manchikanti L, Albers SL,
coronavirus that uses the ACE2 receptor. (RIMECARD Trial [Randomized Clinical et al. Responsible, safe, and effective
Nature 2013; 503:535-538. Trial of Intravenous Infusion Umbilical use of biologics in the management
Cord Mesenchymal Stem Cells on
52. Hamming I, Timens W, Bulthuis ML, Cardiopathy]). Circ Res 2017; 121:1192- of low back pain: American Society of
et al. Tissue distribution of ACE2 1204. Interventional Pain Physicians (ASIPP)
protein, the functional receptor for guidelines. Pain Physician 2019; 22:S1-
SARS coronavirus. A first step in 63. Shafei AE, Ali MA, Ghanem HG, et S74.
understanding SARS pathogenesis. J al. Mesenchymal stem cell therapy: 75. Sanapati J, Manchikanti L, Atluri S, et
Pathol 2004; 203:631-637. A promising cell-based therapy for al. Do regenerative medicine therapies
treatment of myocardial infarction. J
53. Iwata-Yoshikawa N, Okamura T, Shimizu Gene Med 2017; 19:12. provide long-term relief in chronic
Y, Hasegawa H, Takeda M, Nagata N. 64. Driscoll J, Patel T. The mesenchymal low back pain: A systematic review
TMPRSS2 Contributes to Virus Spread and metaanalysis. Pain Physician 2018;
and Immunopathology in the Airways stem cell secretome as an acellular 21:515-540.
of Murine Models after Coronavirus regenerative therapy for liver disease. J 76. Manchikanti L, Centeno CJ, Atluri S,
Infection. J Virol 2019; 5:6. Gastroenterol 2019; 54:763-773. et al. Bone marrow concentrate (BMC)
54. Behnke J, Kremer S, Shahzad T, et al. 65. Hu C, Zhao L, Wu Z, Li L. Transplantation therapy in musculoskeletal disorders:
MSC-based therapies-new perspectives of mesenchymal stem cells and Evidence-based policy position
for the injured lung. J Clin Med 2020; their derivatives effectively promotes statement of American Society of
3:9. liver regeneration to attenuate Interventional Pain Physicians (ASIPP).
acetaminophen-induced liver injury. Pain Physician 2020; 23:E83-E129.
55. Cruz FF, Rocco PRM. The potential of Stem Cell Res Ther 2020; 11:88.
mesenchymal stem cell therapy for 77. Pean CA, Kingery MT, Strauss E, Bosco
chronic lung disease. Expert Rev Respir 66. Heydari Z, Najimi M, Mirzaei H, et al. J, Halbrecht J. Direct to consumer
Med 2020; 14:31-39. Tissue engineering in liver regenerative advertising of stem cell clinics: Ethical
medicine: insights into novel considerations and recommendations
56. Li D, Liu Q, Qi L, Dai X, Liu H, Wang translational technologies. Cells 2020;
Y. Low levels of TGF-β1 enhance human 9:2. for the healthcare community. J Bone
umbilical cord-derived mesenchymal Joint Surg Am 2019; 101:e103.
stem cell fibronectin production and 67. Missoum A. Recent Updates on 78. FTC stops deceptive health claims
extend survival time in a rat model of Mesenchymal Stem Cell Based Therapy by a stem cell therapy clinic. Federal
lipopolysaccharide-induced acute lung for Acute Renal Failure. Curr Urol 2020; Trade Commission. October 18, 2018.
injury. Mol Med Rep 2016; 14:1681-1692. 13:189-199. Accessed date 3/18/2020.
57. SIAARTI. Pro Vita Contra Dolorem 68. Qian X, Xu C, Fang S, et al. Exosomal www.ftc.gov/news-events/press-
Semper. Raccomandazioni di etica MicroRNAs derived from umbilical releases/2018/10/ftc-stops-deceptive-
clinica per l’ammissione a trattamenti mesenchymal stem cells inhibit health-claims-stem-cell-therapy-clinic
intensivi e per la loro sospensione, in hepatitis C virus infection. Stem Cells 79. Daley GQ. Polar extremes in the clinical
condizioni eccezionali di squilibrio tra Transl Med 2016; 5:1190-1203. use of stem cells. N Engl J Med 2017;
necessità e risorse disponibili - versione 69. Gao L, Zhong X, Jin J, Li J, Meng XM. 376:1075-1077.
01 Pubblicato il 06.03.2020. Potential targeted therapy and diagnosis 80. FDA News Release. FDA acts to remove
58. Iyer SS, Co C, Rojas M. Mesenchymal based on novel insight into growth unproven, potentially harmful treatment
stem cells and inflammatory lung factors, receptors, and downstream used in ‘stem cell’ centers targeting
diseases. Panminerva Med 2009; 51:5-16. effectors in acute kidney injury and vulnerable patients. Vaccinia Virus
acute kidney injury-chronic kidney
59. Abraham A, Krasnodembskaya A. disease progression. Signal Transduct Vaccine (Live) seized after being used
Mesenchymal stem cell-derived Target Ther 2020; 5:9. inappropriately in vulnerable cancer
extracellular vesicles for the treatment patients. August 28, 2017. Accessed date
of acute respiratory distress syndrome. 70. Hu J, Yu X, Wang Z, et al. Long term 3/18/2020
Stem Cells Transl Med 2020; 9:28-38. effects of the implantation of Wharton’s www.fda.gov/NewsEvents/Newsroom/
jelly-derived mesenchymal stem cells

www.painphysicianjournal.com E81